3 September 2026
Discover how dsm-firmenich advances patient-centric medical nutrition with taste and sensory solutions designed to improve acceptance, adherence and enjoyment.
8 July 2026
dsm-firmenich awards five Nutrition Research Grants to advance healthy longevity research across Asia Pacific, supporting innovative nutrition solutions for healthy aging.
8 July 2026
Nominations in ingredient and product of the year categories recognize the company’s achievements in advancing omega-3 nutrition from clinical science to consumer shelf.
25 March 2026
Visitors to booth #3C88 in Barcelona this May can explore how dsm-firmenich is unlocking increased health expectancy with the latest science-backed innovations targeting the cellular hallmarks of aging
19 March 2026
dsm-firmenich announces the launch of a new technology, ModulaSENSE® Bitter, designed to help pharmaceutical companies improve the taste of drugs and increase patient adherence.
11 March 2026
dsm-firmenich has announced the completion of a planned $10 million modernization program on its Schenectady premix facility in the United States, transforming the site into a flagship premix hub for the Americas.
5 March 2026
The company continues its regulatory success in Asia’s early life nutrition market with approval of four new HMOs in Malaysia and Thailand alongside commercial authorization of its 3’-SL ingredient in China
16 September 2025
For the first time at SupplySide Global, visitors can step inside an interactive journey that redefines how we think about longevity with dsm-firmenich at booth #6264.
2 July 2025
New clinical evidence reveals that a capsule-based biotic mixture of pre- and probiotics as well as microencapsulated sodium butyrate may provide fast and effective relief from gastrointestinal symptoms in adults with Irritable Bowel Syndrome (IBS) in as early as four weeks.
2 June 2025
dsm-firmenich secures regulatory approval in Indonesia for its 2’-FL HMO ingredient, expanding market access for gut health and nutrition solutions.
29 April 2025
New clinical evidence highlights potential of three-month synbiotic supplementation in attenuating post-exercise malaise and increasing brain metabolites in adults with post-COVID-19 chronic fatigue syndrome (CFS).
14 April 2025
dsm-firmenich, a leading innovator in health, nutrition and beauty, is set to showcase solutions that advance nutrition at Vitafoods Europe 2025 on booth 3G58 with a display of its latest innovations in healthy longevity, gut health and more.
11 April 2025
dsm-firmenich, a global innovator in health, nutrition and beauty, has today announced the approval of its human milk oligosaccharide (HMO), 2'-O-Fucosyllactose (2'-FL)—commercially known as GLYCARE® 2FL—as a functional ingredient for early life nutrition in India. This regulatory milestone marks a new opportunity to enhance infant health, as well as support HMO innovation in the region, with GLYCARE® 2FL representing dsm-firmenich’s first HMO approval in India.
2 April 2025
Evidence from a clinical study deepens insight into role of the gut-brain axis, marking progress towards a more holistic strategy for managing gastrointestinal (GI), irritability and anxiety-related symptoms in autistic children with synbiotics, either alone or in combination with gut-directed hypnotherapy (GDH).
1 April 2025
”At dsm-firmenich, we are committed to advancing vascular care with innovative biomaterial solutions that support the goals of driving better clinical outcomes, reducing healthcare costs, and improving the lives of patients worldwide. We are very excited to formally collaborate with Peijia to bring progress to life in China.” - Paul Spencer, President of the Biomedical Division.
26 March 2025
dsm-firmenich and MedAccess collaborate to ensure affordable vitamin A for edible oil fortification, improving nutrition in vulnerable communities.
20 March 2025
dsm-firmenich wins a UK patent lawsuit, protecting its breakthrough algal DHA oil technology and reinforcing its commitment to innovation.
13 March 2025
dsm-firmenich launches taste solutions for pharma, enhancing drug palatability and market readiness with expert-backed flavors, maskers, and sensates.
20 February 2025
dsm-firmenich, a leading innovator in health, nutrition, and beauty reveals new clinical data confirming that the bioavailability of cannabidiol (CBD)-based therapies can be enhanced in oral solid dosage forms.
27 November 2024
Five research projects are set to advance gut health research in the Asia-Pacific region.
7 November 2024
dsm-firmenich, innovators in health, nutrition, and beauty, together with Rohto Pharmaceutical, announced the market launch in Japan of Vision R made with the dsm-firmenich patented Sprinkle It Technology™ (SIT), multi-layered micronutrient granules designed to address nutritional insufficiencies amongst seniors, in support of healthy longevity.
4 November 2024
dsm-firmenich has undergone an impressive transformation: from a mining company to a global leader in health, nutrition, and beauty. At its headquarters in Maastricht, we spoke with Guyomard Beckers, Senior Director of Digital Transformation at dsm-firmenich Biomedical, about digital transformation and how AI is shaping the future of the company’s biomedical activities.
29 October 2024
dsm-firmenich, innovators in health, nutrition, and beauty, announced the launch of Dry Vit A Palmitate for Early Life Nutrition – a breakthrough clean-label solution designed to enhance the nutritional value of infant formulas without the stability issues associated with traditional vitamin A ingredients.
23 October 2024
dsm-firmenich, innovators in health, nutrition, and beauty, has grown its leading-edge life’s® portfolio with the worldwide launch of life’sDHA® B54-0100 – the company’s most naturally potent algal docosahexaenoic acid (DHA) oil to date.
20 September 2024
dsm-firmenich, leading innovator in health, nutrition and beauty, today announced the launch of Dry Vitamin A Palmitate NI – a new form of dry vitamin A – as a stable, clean label solution for combating widespread nutrient deficiency through flour fortification.
12 September 2024
This October, dsm-firmenich, innovators in nutrition, health, and beauty, invites stakeholders across the pharmaceutical industry to immerse themselves in its patient-inspired innovations at CPHI 2024.
3 September 2024
The Biomedical division of dsm-firmenich is thrilled to announce the advancement of Robyn Wiseman to the role of Vice President of Global Commercial. Beginning August 26, 2024, Robyn will lead the global commercial team located throughout the Americas, EMEA, and APAC.
30 August 2024
dsm-firmenich, a global innovator in health, nutrition and beauty, today announced the successful approval of its human milk oligosaccharide (HMO): 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as novel food ingredients in the United Kingdom and European Union.
29 August 2024
dsm-firmenich announces that the United States Patent and Trademark Office (USPTO) rejected Honeywell’s request for inter partes review (IPR) and cancellation of dsm-firmenich’s U.S. Patent No. 10,280,532, claiming a colored multi-filament yarn. The protected inventions are useful in medical devices, such as colored Ultra High Molecular Weight Polyethylene (UHMWPE) sutures.
15 July 2024
Following an extensive global search process conducted by Legacy MEDSearch, dsm-firmenich is thrilled to announce the appointment of Paul Spencer as the new President of the Biomedical business. Spencer will replace former President, John Witkowski.
25 June 2024
dsm-firmenich has announced the launch of CBtru® – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.
8 May 2024
dsm-firmenich and Indena will introduce dietary supplement solutions combining biotics with botanicals in enjoyable delivery formats, offering an enhanced flavor and taste experience, at Vitafoods Europe 2024.
7 May 2024
dsm-firmenich, innovators in nutrition, health, and beauty, has announced the approval of its ampli-D® calcidiol monohydrate ingredient as a novel food in the EU by the European Commission.
24 April 2024
dsm-firmenich, innovators in nutrition, health and beauty, and Lallemand Health Solutions, pioneers in probiotics, today announce a groundbreaking partnership to launch new synergistic synbiotic solutions for early life nutrition.
3 April 2024
dsm-firmenich is proud to announce its new strategic collaboration with Oz Medicann Group (OMG), to explore the therapeutic potential of cannabidiol (CBD) bases orally dispersible tablets addressing insomnia.
4 March 2024
dsm-firmenich, the leading innovator in health, nutrition and beauty, has announced an exciting new partnership with SCN BestCo to develop and market advanced omega-3 gummies in the US.
27 February 2024
Biomedical, a subsidiary of dsm-firmenich, is excited to announce that it has made a significant investment in a new facility, supporting its business portfolio growth.
26 January 2024
dsm-firmenich, a leading innovator in nutrition, health, and beauty, is pleased to announce a victory that it prevailed before the United States Patent and Trademark Office (USPTO) today, by successfully defending a patent from an invalidation action recently levied by Mara Renewables Corporation.
15 January 2024
dsm-firmenich, a leading innovator in health, nutrition and beauty, is delighted to announce that it has gained approval for an additional four human milk oligosaccharide (HMO) ingredients for use as nutritive substances in infant formula products in Australia and New Zealand.
13 December 2023
dsm-firmenich, a leading innovator in health, nutrition and beauty, announced that it has secured market access for its 3-fucosyllactose (3-FL) human milk oligosaccharide (HMO) ingredient in the European Union (EU).
25 October 2023
Indena, a private Italian company with a century of experience in the identification, development and production of high-quality, innovative and effective active botanical principles for the pharmaceutical and health food industries, and dsm-firmenich, innovators in nutrition, health and beauty, have announced a strategic partnership in some specific areas.
19 October 2023
dsm-firmenich, the leading innovator in health, nutrition and beauty, today announces the upcoming North American launch of life’s®OMEGA O3020, the first and only single-source algal omega-3 with the same eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) ratio naturally found in standard fish oil, but with twice the potency.
18 October 2023
dsm-firmenich is proud to announce its strategic partnership with Bod Science, an Australian-based pioneer in medical cannabis.
3 October 2023
Following the merger of two iconic companies – DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care.
5 September 2023
DSM Biomedical joins the ICMS Industrial Consortium to advance sustainable healthcare innovations by connecting its experts with leading researchers in smart materials and nanomedicine, fostering collaboration for impactful solutions.
10 August 2023
dsm-firmenich, innovator in health, nutrition and beauty, today announced that it has received ‘no questions’ response letters from the US Food and Drug Administration (FDA) to its Generally Recognized as Safe (GRAS) notices submitted by Glycom A/S* for three new human milk oligosaccharide (HMO) ingredients.
10 August 2023
dsm-firmenich, the leading innovator in health, nutrition and beauty, today announced that its human milk oligosaccharide (HMO) ingredients, GlyCare™ 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT), have been approved as food additives (nutrition fortifiers) in China.
10 August 2023
dsm-firmenich, the leading innovator in health, nutrition and beauty, is to showcase how it is “bringing progress to life” in the human health arena at SupplySide West 2023 – spotlighting its purpose-led innovation platforms to deliver solutions for gut support, cognitive performance, and women’s wellness.
12 July 2023
dsm-firmenich, the leading innovator in health, nutrition and beauty, confirmed plans to expand its human milk oligosaccharide (HMO) portfolio in China with two new ingredient submissions to the China National Center for Food Safety Risk Assessment (CFSA) and National Health Committee (NHC).
3 July 2023
dsm-firmenich, innovators in nutrition, health, and beauty, confirms the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million.
27 March 2023
Royal dsm-firmenich, a global science-based company active in Health, Nutrition & Bioscience, is to reveal its latest purpose-led concepts for fast-tracked nutrition innovation across all life stages at Vitafoods Europe 2023.
8 March 2023
DSM Biomedical introduces ISCC-certified Bio-based Dyneema Purity® fiber, enabling renewable UHMWPE options for medical devices without supply disruption. Launching in 2024, this sustainable solution supports industry ESG goals and promotes a circular economy.
1 March 2023
Hologram Sciences, a consumer-facing health tech company building holistic personalized nutrition solutions, and Haleon (NYSE: HLN), a global leader in consumer health, have entered into a strategic collaboration focused on innovation to address consumer health concerns in areas such as healthy aging.
20 January 2023
Royal DSM, a global, purpose-led, science-based company, partnered with Atlantia Clinical Trials Ltd., a world leading contract research organisation to explore the potential benefits of DSM’s Fruitflow® on gut microbiota and cardiovascular health through the gut-heart axis.
7 November 2022
Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, today announced that its human-identical milk oligosaccharide (HMO) GlyCare™ 2’-fucosyllactose (2FL) has been approved in Canada for use in infant formula and nutritional supplements (toddler formula).
7 November 2022
Royal DSM, a global science-based company active in Health, Nutrition & Bioscience, forms a new strategic partnership with LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution. The agreement will leverage LBB Specialties’ market expertise to improve customer service levels and increase market share for DSM’s broad ingredient offering for the North American dietary supplements market.
26 October 2022
Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, comments on the findings from a recently published paper in Nature Medicine which reported that those infected with COVID-19 are at increased risk of long-term neurologic disorders that persist post infection. These symptoms are one part of what is now known as “long COVID”, which is estimated to impact 7.5% of adults in the total US population.
12 October 2022
Hologram Sciences, a consumer-facing personalized nutrition company, and Maeil Health Nutrition, a leader in functional nutrition, are joining forces in a strategic partnership to deliver personalized nutrition solutions to the Korean market.
22 April 2022
DSM announces the launch of a new sustainably-focused campaign that encourages the use of algae-derived omega-3 ingredients. DSM aims to educate global audiences on the impact of overfishing on the marine ecosystem.
30 March 2022
Biomedical and Svelte Medical Systems Collaboration Fuels Development of DISCREET Bioresorbable Coating Technology Used with SLENDER IDS® and DIRECT RX® Bioresorbable Coated Drug-Eluting Stent (DES) Systems
23 February 2022
Hologram Sciences, the personalized nutrition pioneer, is targeting a revolution in health & wellness with the unveiling of its new consumer brand concepts addressing key health concerns through novel data-driven approaches.
17 February 2022
Royal DSM, a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living, today announced that it has bolstered its capabilities as an end-to-end partner for North American customers in the gut health space with FDA NDI status strains.
10 January 2022
DSM Biomedical partners with NC Biomatrix to advance VitaDisc, a regenerative treatment for degenerative disc disease, aiming to transform back pain care and improve patient outcomes globally.
18 October 2021
dsm-firmenich is proud to announce its strategic partnership with Zerion Pharma, to unlock a new era in cannabinoid innovation.
Browse our archive of past press releases from DSM Human Nutrition & Health, showcasing key announcements, products, concepts and more.
もっと古いものをお探しですか？2022年以前のプレスリリースアーカイブをご覧ください。
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Learn how integrating taste and sensory science early in medical nutrition development can improve patient acceptance, adherence, and product success.
Experts discuss the impacts of taste and smell alterations in cancer patients—and how medical nutrition can better address them.
Discover how FSSC 22000 certification at CREAAS elevates dietary supplement co-creation, blending clinical excellence with expert application development.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.